Results 11 to 20 of about 182,378 (301)
S-LoRA: Serving Thousands of Concurrent LoRA Adapters
, 2023 The "pretrain-then-finetune" paradigm is commonly adopted in the deployment of large language models. Low-Rank Adaptation (LoRA), a parameter-efficient fine-tuning method, is often employed to adapt a base model to a multitude of tasks, resulting in a substantial collection of LoRA adapters derived from one base model.
Sheng, Ying +11 more
openaire +2 more sources
Efficient vertical handover in heterogeneous low-power wide-area networks [PDF]
, 2020 As the Internet of Things (IoT) continues to expand, the need to combine communication technologies to cope with the limitations of one another and to support more diverse requirements will proceed to increase. Consequently, we started to see IoT devices
De Poorter, Eli +3 more
core +1 more source
Defining Roles in Pediatric Palliative Care: Perspectives From Oncology and Palliative Care Teams
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Early integration of pediatric palliative care (PPC) is associated with improved symptom management, quality of life, and healthcare utilization for children with cancer. Despite this, variation persists in how PPC is understood, operationalized, and integrated within pediatric oncology programs. In particular, ambiguity surrounding
Leeat Granek +13 more
wiley +1 more source
LoRa in a haystack: a study of the LORA signal behavior [PDF]
2019 International Conference on Wireless and Mobile Computing, Networking and Communications (WiMob), 2019 Over the years, LoRa has been raising a lot of interest, both from the academia and the industry. LoRa is indeed a promising technology that enables long range and low power communications to connect IoT devices to the Internet. LoRa is often envisioned for several applications such as regular reporting but it is also aimed to be exploited for other ...
Amadou, Ibrahim +2 more
openaire +2 more sources
KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer
Molecular Oncology, EarlyView.Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan +16 more
wiley +1 more source
Sertraline Treatment Can Mimic Niemann‐Pick Type C Biomarker Profile: A Diagnostic Pitfall
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Oxysterols (cholestane‐3β,5α,6β‐triol and 7‐ketocholesterol) and N‐palmitoyl‐O‐phosphocholineserine (PPCS) are sensitive biomarkers for Niemann‐Pick disease type C (NPC) screening. However, false‐positive results occur, with a biomarker profile suggestive of NPC despite the absence of pathogenic variants in genes involved in NPC or ...
Maria Makrygianni +19 more
wiley +1 more source
The Oncologist, EarlyView., 2021 Abstract Background LIBRETTO‐001 is an ongoing, global, open‐label, phase I/II study of selpercatinib in patients with advanced or metastatic solid tumors. We report interim patient‐reported outcomes in patients with RET fusion–positive non‐small cell lung cancer (NSCLC).
Anna Minchom +11 more
wiley +1 more source
Science Secrets under the Ice [PDF]
, 2007 Lora Koenig ’99 spent a summer in Antarctica collecting data about Earth’s ...
Davis, Laura
core +1 more source
Arthritis Care &Research, EarlyView.Objective Knee osteoarthritis (OA) commonly affects individuals with type 2 diabetes (T2DM) and is associated with increased risk of diabetes‐related complications. To better understand potential mechanisms, we examined the association between symptomatic knee OA and glycemic control in individuals with T2DM.
Lauren K. King +10 more
wiley +1 more source
The Oncologist, EarlyView., 2021 Abstract Background Medullary thyroid cancer (MTC) standard of care includes multikinase inhibitors (MKIs), which can exacerbate disease‐related diarrhea, primarily because of non‐RET kinase inhibition. We report diarrhea and other patient‐reported outcomes (PROs) with selpercatinib, a highly selective RET inhibitor, among patients with RET‐mutant MTC ...
Lori J. Wirth +10 more
wiley +1 more source